Login to Your Account

BresaGen, British Biotech See Setbacks Continue As E21R Fails

By Mark Lawson and Nuala Moran

Wednesday, July 31, 2002
SYDNEY, Australia - Unfavorable results from clinical trials have stopped another collaborative project involving an Australian biotech company, despite favorable preclinical trials. BresaGen Ltd. and British Biotech plc abandoned a collaborative agreement to develop E21R as a treatment for acute myeloid leukemia (AML). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription